enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA (siRNA, shRNA, lncRNA etc.) with broad tissue and disease applications. In addition to developing EG-70 for BCG-unresponsive NMIBC, enGene is developing unique genetic medicines for respiratory indications. The company is also evolving its technology to enable applications in several mucosal tissues such as the nasal and genital mucosa as well as the gastrointestinal tract among others.
enGene is supported financially by top-tier institutional investors including Forbion Capital Partners, Fonds de Solidarité FTQ, Pharmstandard International S.A., Lumira Capital and Johnson & Johnson Development Corporation.
enGene is supported financially by top-tier institutional investors including Forbion Capital Partners, Fonds de Solidarité FTQ, Pharmstandard International S.A., Lumira Capital and Johnson & Johnson Development Corporation.
Location: Canada, Montreal (06), Montreal
Employees: 51-200
Founded date: 1999
Investors 4
| Date | Name | Website |
| 13.07.2025 | Foresite C... | foresiteca... |
| 10.03.2024 | Omega Fund... | omegafunds... |
| 02.02.2026 | Hercules C... | htgc.com |
| 12.01.2023 | Forbion | forbion.co... |
Mentions in press and media 11
| Date | Title | Description |
| 25.06.2025 | FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer | BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerati... |
| 02.05.2024 | enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual M... | Oral presentation highlights rational design of EG-70 to address challenges faced by other intravesical treatment options, including preparation, handling, and safety considerations BOSTON and MONTREAL, May 2, 2024 /PRNewswire/ - enGene Hol... |
| 02.11.2023 | Lumira Ventures Portfolio Company enGene (Nasdaq: ENGN) Debuts as Publicly Traded Genetic Medicines Company | CAD$191 million gross proceeds from the transaction to support the advancement of the clinical program and pipeline expansion |
| 27.05.2021 | Lumira Portfolio Company, enGene, Announces First-in-Human Dosing of EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer in Phase 1/2 Clinical Trial | BOSTON and MONTRÉAL, May 27, 2021: enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced the dosing of ... |
| 27.05.2021 | enGene Announces First-in-Human Dosing of EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer in Phase 1/2 Clinical Trial | |
| 03.12.2020 | enGene Receives Fast Track Designation for EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer | |
| 02.11.2020 | enGene Announces FDA Clearance of IND Application for EG-70, an intravesical dual-immune modulator for the treatment of non-muscle invasive bladder cancer | |
| 29.10.2020 | enGene Receives Funding Through Cystic Fibrosis Foundation's Path to a Cure for the Discovery of Novel Gene Therapies to Treat Cystic Fibrosis | |
| 09.01.2020 | enGene Expands Senior Management Team | BOSTON and MONTRÉAL /PRNewswire/ – enGene Inc., the biotechnology company developing rationally designed gene therapies targeted to mucosal tissues through its proprietary non-viral vector DDX® platform, today announced the appointments of ... |
| 29.05.2019 | enGene Appoints José M. Lora, Ph.D. as Chief Scientific Officer | MONTRÉAL and BOSTON, May 29, 2019 — enGene Inc., the high growth biotechnology company developing the Gene Pill™ – a robust, proprietary non-viral vector platform to deliver gene therapies via oral administration – today announced the appoi... |
Show more